Novartis' Investigational Medicine Shows Potent Activity Against Drug-Resistant Malaria Strains

benzinga.com/news/health-care/25/11/48842681/novartis-investigational-medicine-shows-potent-activity-against-drug-resistant-malaria-strains

Novartis AG (NYSE:NVS) released data on Thursday from the KALUMA Phase 3 study for the new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum).
GanLum is a combination of two compounds: ganaplacide, a novel compound with an entirely new mechanism of action, and a new once-daily…

This story appeared on benzinga.com, 2025-11-13 17:33:20.
The Entire Business World on a Single Page. Free to Use →